Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...
Feb 15 (Reuters) - The U.S. Food and Drug Administration approved British drugmaker GSK's (GSK.L), opens new tab combination vaccine to protect against meningococcal infection for use in people ...
Feb 14 (Reuters) - Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK (GSK.L), opens new tab, the Financial Times reported on Friday. Citadel has ...
On this front GSK scores very highly, with dividend cover standing at 2.6 times and 2.7 times for 2025 and 2026 respectively. The next stage is to consider the firm’s balance sheet. A sturdy ...
GSK has claimed its second breakthrough designation from the FDA for antibody-drug conjugate GSK5764227, which it licensed from China's Hansoh Pharma in a $1.7 billion deal. The status has been ...
GSK's business development team have been working overtime of late, with three R&D deals announced in the last few days across Alzheimer's disease and cancer. The Alzheimer's agreement – with ...
A team can win a game but fail to cover the spread if they don’t win by enough points. A push happens if the outcome of the game is the same amount as the spread; in this case, bets are returned.